Production of interstitial pneumonia in mice and rats by administration of component preparations of mycoplasma, lectins and other non-viable compounds, and screening for the protective immunogen components of Mycoplsma pulmonis

利用肺支原体分离的成分制备了小鼠和大鼠肺支原体所致间质性肺炎的各种肺部病变特征，为研究肺支原体感染的化疗研究和筛选小鼠肺支原体所致肺炎的保护性免疫原奠定基础。通过给药无活性成分产生间质性肺炎：我们能够几乎完全复制间质性肺炎，其中从支原体感染的早期到晚期，可以在肺中看到淋巴细胞浸润血管周围和肺泡壁，通过鼻内给药一种复方肾炎苷（对肺具有交叉反应性抗原性）和ConA。具有丝裂原活性和支原体培养滤液纯化抗原的抗原性。然而，气管内和支气管周围的炎症只能由肺分枝杆菌纯化膜引起。我们认为，这些症状发展为慢性间质性肺炎需要感染引起的宿主全身免疫改变。单独使用抗生素对这种肺炎没有足够的治疗效果。相比之下，免疫抑制剂（强的松龙、环孢素A）和免疫调节剂（白细胞介素-2）与抗生素（米诺霉素）联合使用可以产生治疗效果，使用这些药物的研究仍在继续探索它们的作用机制，以确定有效的治疗方案。本研究中使用的实验性小鼠感染系统对肺支原体诱导的小鼠肺炎进行主动和被动免疫，提供了经验证据，证明生物体中存在抗原成分，可以显著增强小鼠对肺支原体的保护作用。

Using components isolated from Mycoplasma pulmonis, we prepared various lung lesions characteristic of mycoplasma-induced interstitial pneumonia in the mouse and rat to clarify the character of this form of pneumonia as a basis for the investigation of chemotherapy of mycoplasma infections and screening for a protective immunogen to M.pulmonis-induced pneumonia in mice. Production of iterstitial pneumonia by administration of non-viable components:We were able to almost completely reproduce interstitial pneumonia in which perivascular and alveolar wall infiltration by lymphocytes can be seen in the lung from the early to maximum phase of mycoplasma infection by intranasal administration of a compound nephritogenoside, which has cross-reactive antigenicity towards the lung, and ConA, which has mitogen activity and the antigenicity of purified antigen isolated from mycoplasma culture filtrate. However, intratracheal and peribroncheal inflammations could only be induced by administration of the purified membrane of M.pulmonis. It is believed that infection-induced systemic immunological change of the host is requisite for these symptoms to develop into chronic interstitial pneumonia. Administration of antibiotics alone does not have an adequate therapeutic effect on this pneumonia. By contrast, combined administration of the immunosuppressants (prednisolone, cyclosporin A) and the immunomodulator (interleukin-2) with the antibiotic (minomycine) leads to therapeutic efficacy and studies using these drugs are still continuing to explore the mechanisms on which they act to determine an efficacious from of therapy. The experimental mouse-based infection system used in the present study for active and passive immunization of M.pulmonis-induced pneumonia in mice provided empirical evidence of the existence of antigenic components of organisms that offer significantly greater protection of mice against M.pulmonis.